A comprehensive comparison of DNA and RNA vaccines

被引：19

作者：

Wang, Chunxi ^{[1
]}

Yuan, Fan ^{[1
]}

机构：

[1] Duke Univ, Dept Biomed Engn, Durham, NC 27705 USA

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2024年 / 210卷

基金：

美国国家卫生研究院;

关键词：

Nucleic acid vaccine; COVID-19; Infectious disease; Cancer vaccine; MESSENGER-RNA; PLASMID DNA; IN-VIVO; MINICIRCLE DNA; LIPID NANOPARTICLES; GENE-EXPRESSION; DENDRITIC CELLS; IMMUNE-RESPONSES; HEALTHY-ADULTS; OPEN-LABEL;

D O I：

10.1016/j.addr.2024.115340

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Nucleic acid technology has revolutionized vaccine development, enabling rapid design and production of RNA and DNA vaccines for prevention and treatment of diseases. The successful deployment of mRNA and plasmid DNA vaccines against COVID-19 has further validated the technology. At present, mRNA platform is prevailing due to its higher efficacy, while DNA platform is undergoing rapid evolution because it possesses unique advantages that can potentially overcome the problems associated with the mRNA platform. To help understand the recent performances of the two vaccine platforms and recognize their clinical potentials in the future, this review compares the advantages and drawbacks of mRNA and DNA vaccines that are currently known in the literature, in terms of development timeline, financial cost, ease of distribution, efficacy, safety, and regulatory approval of products. Additionally, the review discusses the ongoing clinical trials, strategies for improvement, and alternative designs of RNA and DNA platforms for vaccination.

引用

页数：19

共 234 条

[1] Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration [J].

AboulFotouh, Khaled ;

Cui, Zhengrong ;

Williams, Robert O., III .

AAPS PHARMSCITECH, 2021, 22 (03)

[2] Gene transfer into muscle by electroporation in vivo [J].

Aihara, H ;

Miyazaki, J .

NATURE BIOTECHNOLOGY, 1998, 16 (09) :867-870

[3] A combinatorial library of lipid-like materials for delivery of RNAi therapeutics [J].

Akinc, Akin ;

Zumbuehl, Andreas ;

Goldberg, Michael ;

Leshchiner, Elizaveta S. ;

Busini, Valentina ;

Hossain, Naushad ;

Bacallado, Sergio A. ;

Nguyen, David N. ;

Fuller, Jason ;

Alvarez, Rene ;

Borodovsky, Anna ;

Borland, Todd ;

Constien, Rainer ;

de Fougerolles, Antonin ;

Dorkin, J. Robert ;

Jayaprakash, K. Narayanannair ;

Jayaraman, Muthusamy ;

John, Matthias ;

Koteliansky, Victor ;

Manoharan, Muthiah ;

Nechev, Lubomir ;

Qin, June ;

Racie, Timothy ;

Raitcheva, Denitza ;

Rajeev, Kallanthottathil G. ;

Sah, Dinah W. Y. ;

Soutschek, Juergen ;

Toudjarska, Ivanka ;

Vornlocher, Hans-Peter ;

Zimmermann, Tracy S. ;

Langer, Robert ;

Anderson, Daniel G. .

NATURE BIOTECHNOLOGY, 2008, 26 (05) :561-569

[4] Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses [J].

Alameh, Mohamad-Gabriel ;

Tombacz, Istvan ;

Bettini, Emily ;

Lederer, Katlyn ;

Sittplangkoon, Chutamath ;

Wilmore, Joel R. ;

Gaudette, Brian T. ;

Soliman, Ousamah Y. ;

Pine, Matthew ;

Hicks, Philip ;

Manzoni, Tomaz B. ;

Knox, James J. ;

Johnson, John L. ;

Laczko, Dorottya ;

Muramatsu, Hiromi ;

Davis, Benjamin ;

Meng, Wenzhao ;

Rosenfeld, Aaron M. ;

Strohmeier, Shirin ;

Lin, Paulo J. C. ;

Mui, Barbara L. ;

Tam, Ying K. ;

Kariko, Katalin ;

Jacquet, Alain ;

Krammer, Florian ;

Bates, Paul ;

Cancro, Michael P. ;

Weissman, Drew ;

Prak, Eline T. Luning ;

Allman, David ;

Locci, Michela ;

Pardi, Norbert .

IMMUNITY, 2021, 54 (12) :2877-+

[5] Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial [J].

Alberer, Martin ;

Gnad-Vogt, Ulrike ;

Hong, Henoch Sangjoon ;

Mehr, Keyvan Tadjalli ;

Backert, Linus ;

Finak, Greg ;

Gottardo, Raphael ;

Bica, Mihai Alexandru ;

Garofano, Aurelio ;

Koch, Sven Dominik ;

Fotin-Mleczek, Mariola ;

Hoerr, Ingmar ;

Clemens, Ralf ;

von Sonnenburg, Frank .

LANCET, 2017, 390 (10101) :1511-1520

[6]

Almeida AM, 2021, METHODS MOL BIOL, V2197, P207, DOI 10.1007/978-1-0716-0872-2_11

[7] Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models [J].

Andrade, Viviane M. ;

Maricic, Igor ;

Kalia, Richa ;

Jachimowicz, Lauren ;

Bedoya, Olivia ;

Kulp, Daniel W. ;

Humeau, Laurent ;

Smith, Trevor R. F. .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (03)

[8]

[Anonymous], Moderna Announces mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints In Phase 3 Trial In Older Adults

[9]

[Anonymous], Spikevax (Moderna COVID-19 Vaccine) FDA Approval History

[10]

[Anonymous], ZyCoV-D COVID-19 Vaccine

← 1 2 3 4 5 6 7 8 9 10 →